Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from RELIEF THERAPEUTICS Holding ( (CH:RLF) ).
Relief Therapeutics has announced an extraordinary general meeting to seek shareholder approval for a business combination with NeuroX Group SA. The meeting will address proposals including a capital increase and board member elections, aiming to rename the combined entity MindMaze Therapeutics Holding SA. This strategic move is expected to enhance Relief’s position in the biopharmaceutical industry by integrating NeuroX’s advanced neurotherapeutic technologies, potentially benefiting stakeholders through expanded treatment options and market reach.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF2.50 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a Geneva-based biopharmaceutical company focused on developing innovative treatments for rare and debilitating diseases. The company specializes in drug delivery systems and drug repurposing, with a clinical pipeline targeting rare dermatological, metabolic, and respiratory conditions. Relief Therapeutics has successfully commercialized several products through licensing and distribution partnerships.
Average Trading Volume: 41,615
Technical Sentiment Signal: Hold
Current Market Cap: CHF33.98M
See more insights into RLF stock on TipRanks’ Stock Analysis page.